Determination of Biological Activity of Human-enriched Serum Following Chondractiv™ Plus Ingredient Ingestion

The clinical study will be conducted in two phases.

• The first phase will aim at characterizing the metabolites present in human serum after consumption of the Chondractiv™ ingredient and at determining the overall absorption peak of the tested ingredient.
• The second phase will involve collecting sera enriched with metabolites at the absorption peak, following the ingestion of the ingredient. Subsequently, the final objective will be to characterize the influence of these sera enriched with metabolites of interest on the behavior of human joint cartilage cell cultures.

Inclusion criteria

• Liver function tests within reference norms.
• Kidney function tests within reference norms.
• Complete blood count (CBC) within reference norms.
• C-reactive protein (CRP) within reference norms.
• Blood pressure compatible with study requirements.
• Non-smoker or occasional smoker (max 5 cigarettes/day or max 10 ml per week of e-liquid with a nicotine concentration of 3 mg/ml).
• Maximum 5 hours of intense sports per week.
• Weight ≥ 60 kg.
• Body Mass Index (BMI) between 20 and 28 kg/m² (exclusive).
• Subjects who are able and willing to comply with the protocol and give their informed written consent.
• Subjects affiliated with the social security.

Exclusion criteria

• Any type of vaccination within the past month.
• Alcohol consumption exceeding WHO standards (Sup. 3 drinks per day for men).
• Ongoing treatment (medication, dietary supplement, or probiotic) and within the four weeks prior to inclusion.
• Known pathology (including seasonal).
• Allergy to the study product
• Individuals following a diet unsuitable for the study (e.g., vegetarian, vegan, or plant-based diets).
• Change in eating habits within the 4 weeks prior to inclusion.
• Medical and/or surgical history deemed incompatible with the trial by the investigator or their representative.
• Persons under guardianship, curatorship, deprived of freedoms, safeguarding justice.
• Refusal to sign the information sheet and consent